ArticleWorld journal of gastroenterology2008
Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.
Article in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review.Journal of clinical laboratory analysis · 2019Pooled it
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Hepatology (Baltimore, Md.) · 2016Trial
- Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.PloS one · 2022Article
- Article
- Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study.Archives of virology · 2021Article
- HCV Phylogeography of the General Population and High-Risk Groups in Cyprus Identifies the Island as a Global Sink for and Source of Infection.Scientific reports · 2019Article
- Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.World journal of hepatology · 2017Review
- Geographic integration of hepatitis C virus: A global threat.World journal of virology · 2016Article
- Distribution of hepatitis C virus genotypes in Arak city, central province of Iran.Iranian journal of microbiology · 2016Article
- Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.World journal of gastroenterology · 2016Review
- Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.Medicine · 2016Observational
- The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey.Jundishapur journal of microbiology · 2016Article
- Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe.Infectious agents and cancer · 2016Review
- Article
- Epidemiology of hepatitis C in Croatia in the European context.World journal of gastroenterology · 2015Review
- Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen.Journal of clinical microbiology · 2015Article
- [Distribution of HCV genotypes in Chinese Han population with chronic hepatitis C].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2015Article
- Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of kahramanmaras, Turkey.Hepatitis monthly · 2015Article
- Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Nature reviews. Gastroenterology & hepatology · 2015Review
- Global distribution and prevalence of hepatitis C virus genotypes.Hepatology (Baltimore, Md.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo analyze the Hepatitis C virus (HCV) genotype distribution and transmission risk factors in a population of unselected patients in Luxembourg.
methodsEpidemiological information (gender, age and transmission risks) were collected from 802 patients newly diagnosed for hepatitis C and living in Luxembourg, among whom 228 patients referred from prison. Genotyping using 5'noncoding (5'NC) sequencing was performed. We compared categorical data using the Fisher's exact F-test and odds ratios (OR) were calculated for evaluating association of HCV genotype and risk factors.
resultsThe sex ratio was predominantly male (2.2) and individuals aged less than 40 years represented 49.6% of the population. Genotype 1 was predominant (53.4%) followed by genotype 3 (33%). Among risk factors, intravenous drug usage (IVDU) was the most frequently reported (71.4%) followed by medical-related transmission (17.6%) including haemophilia, transfusion recipients and other nosocomial reasons. Genotype 3 was significantly associated to IVDU (OR = 4.84, P < 0.0001) whereas genotype 1 was significantly associated with a medical procedure (OR = 2.42, P < 0.001). The HCV genotype distribution from inmate patients differed significantly from the rest of the population (Chi-square test with four degrees of freedom, P < 0.0001) with a higher frequency of genotype 3 (46.5% vs 27.5%) and a lower frequency of genotype 1 and 4 (44.7% vs 56.8% and 5.3% vs 9.6%, respectively). IVDU was nearly exclusively reported as a risk factor in prison.
conclusionWe report the first description of the HCV genotype distribution in Luxembourg. The repartition is similar to other European countries, with one of the highest European prevalence rates of genotype 3 (33%). Since serology screening became available in 1991, IVDU remains the most common way of HCV transmission in Luxembourg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.